<DOC>
	<DOCNO>NCT02386072</DOCNO>
	<brief_summary>A study identify factor associate improved effectiveness pharmacologic therapy Overactive Bladder , patient perspective primarily measure OAB-Q-SF ( Overactive Bladder Questionnaire Short Form )</brief_summary>
	<brief_title>A Prospective , Observational , Multicenter Study Patients Following Initiation New Course Treatment Overactive Bladder ( OAB )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Muscarinic Antagonists</mesh_term>
	<criteria>Diagnosed OAB ( without urgency incontinence ) treat HCP , symptoms least three month prior study enrollment Initiating new course treatment mirabegron antimuscarinic medication ( include patch formulation ) OAB , may first course treatment OAB , restart switch one drug another Willing able complete PRO questionnaires minimal assistance Current participation clinical trial OAB Use one OAB medication time enrollment Patients whose OAB treat onabotulinumtoxinA , sacral neuromodulation , percutaneous tibial nerve stimulation , external beam radiation ( XRT ) , stent , surgery , intermittent catheterization prior time enrollment Neurologic condition associate OAB symptom Patients reside nursing home</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Betanis®</keyword>
	<keyword>Myrbetriq®</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Antimuscarinics</keyword>
	<keyword>Betmiga®</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Observational</keyword>
</DOC>